Off-the-Shelf CAR-T therapy offers new hope for tough blood cancers
Disease control
Recruiting now
This study tests a new CAR-T therapy called Allo-QuadCAR01-T for people with B-cell cancers that have not responded to other treatments. Unlike current therapies that use a patient's own cells, this one uses donor cells that are ready to use, saving time and reducing cost. It tar…
Phase: PHASE1, PHASE2 • Sponsor: AvenCell Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC